Key result
Chronic hyperviscosity contributes to the pathogenesis of atherosclerosis, hypertension, and metabolic syndrome, while therapeutic phlebotomy may reduce blood pressure and serum glucose levels.
This review highlights the often-overlooked role of blood viscosity in cardiovascular diseases and suggests it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Hyperviscosity may be a cardiometabolic target; leaves open whether phlebotomy improves outcomes without randomized trials.
The pathogenesis of several major cardiovascular diseases, including atherosclerosis, hypertension, and the metabolic syndrome, is not widely understood because the role of blood viscosity is overlooked. Low-density lipoprotein accelerates atherosclerosis by increasing blood viscosity in areas of low flow or shear, predisposing to thrombosis. Atherosclerotic plaques are organized mural thrombi, as proposed by Duguid in the mid-twentieth century. High-density lipoprotein protects against atherosclerosis by decreasing blood viscosity in those areas. Blood viscosity, at the least, contributes to hypertension by increasing systemic vascular resistance. Because flow is inversely proportional to viscosity, hyperviscosity decreases perfusion and glucose utilization by skeletal muscle, contributing to hyperglycemia in the metabolic syndrome. Therapeutic phlebotomy reduces blood pressure and serum glucose levels in the metabolic syndrome by improving blood viscosity.
No takes yet. Share an insight, caveat, or question.
Sloop et al. (2014) conducted a review in Cardiovascular diseases (atherosclerosis, hypertension, metabolic syndrome). Chronic hyperviscosity was evaluated. Chronic hyperviscosity contributes to the pathogenesis of atherosclerosis, hypertension, and metabolic syndrome, while therapeutic phlebotomy may reduce blood pressure and serum glucose levels.
Synapse has enriched 10 related papers. Consider them for comparative context: